Lenzilumab is an engineered anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat cytokine release syndrome preceding lung dysfunction and acute respiratory distress syndrome in serious SARS-CoV-2 infection cases (Bonaventura et al., 2020; Temesgen et al., 2021b). The gene discussed is CSF2; the disease is acute respiratory distress syndrome.